Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct;10(10):e1423-e1442.
doi: 10.1016/S2214-109X(22)00330-8.

The availability, cost, and affordability of essential medicines for asthma and COPD in low-income and middle-income countries: a systematic review

Marie Stolbrink  1 , Helen Thomson  2 , Ruth M Hadfield  3 , Obianuju B Ozoh  4 , Rebecca Nantanda  5 , Shamanthi Jayasooriya  6 , Brian Allwood  7 , David M G Halpin  8 , Sundeep Salvi  9 , Maria Montes de Oca  10 , Kevin Mortimer  11 , Sarah Rylance  12
Affiliations

The availability, cost, and affordability of essential medicines for asthma and COPD in low-income and middle-income countries: a systematic review

Marie Stolbrink et al. Lancet Glob Health. 2022 Oct.

Abstract

Background: Asthma and chronic obstructive pulmonary disease (COPD) cause a considerable burden of morbidity and mortality in low-income and middle-income countries (LMICs). Access to safe, effective, quality-assured, and affordable essential medicines is variable. We aimed to review the existing literature relating to the availability, cost, and affordability of WHO's essential medicines for asthma and COPD in LMICs.

Methods: A systematic review of the literature was done by searching seven databases to identify research articles published between Jan 1, 2010, and June 30, 2022. Studies on named essential medicines for asthma and COPD in LMICs were included and review articles were excluded. Two authors (MS and HT) screened and extracted data independently, and assessed bias using Joanna Briggs Institute appraisal tools. The main outcome measures were availability (WHO target of 80%), cost (compared with median price ratio [MPR]), and affordability (number of days of work of the lowest paid government worker). The study was registered with PROSPERO, CRD42021281069.

Findings: Of 4742 studies identified, 29 met the inclusion criteria providing data from 60 LMICs. All studies had a low risk of bias. Six of 58 countries met the 80% availability target for short-acting beta-agonists (SABAs), three of 48 countries for inhaled corticosteroids (ICSs), and zero of four for inhaled corticosteroid-long-acting beta-agonist (ICS-LABA) combination inhalers. Costs were reported by 12 studies: the range of MPRs was 1·1-351 for SABAs, 2·6-340 for ICSs, and 24 for ICS-LABAs in the single study reporting this. Affordability was calculated in ten studies: SABA inhalers typically cost around 1-4 days' wages, ICSs 2-7 days, and ICS-LABAs at least 6 days. The included studies showed heterogeneity.

Interpretation: Essential medicines for treating asthma and COPD were largely unavailable and unaffordable in LMICs. This was particularly true for inhalers containing corticosteroids.

Funding: WHO and Wellcome Trust.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests KM is an advisory board member for AstraZeneca. DMGH reports honoraria for lecturing, attending advisory boards, and preparing educational materials from Aerogen, AstraZeneca, Boehringer Ingelheim, Chiesi, CSL Behring, GlaxoSmithKline (GSK), Novartis, Pfizer, and Sanofi. RMH has received funding from the Global Initiative for Chronic Obstructive Lung Disease to assist with literature searches. BA reports grants from the National Institutes of Health Research; honoraria from GSK, Novartis, Boehringer Ingelheim, and Cipla Medpro; participation on advisory boards for Cipla Medpro, Boehringer Ingelheim, and Janssen Pharmaceuticals; and support for attending meetings and for travel by Janssen Pharmaceuticals. SS reports honoraria for lectures from Cipla, Glenmark, and GSK. MMdO reports speaker fees from AstraZeneca. All other authors declare no competing interests.

Figures

Figure 1
Figure 1
Study selection
Figure 2
Figure 2
Maps of reported availability of inhaled medicines in LMICs (A) Short-acting beta-agonist inhalers. (B) Inhaled corticosteroid inhalers. (C) Inhaled corticosteroid–long-acting beta-agonist combination inhalers. Availability means presence of inhaled medicines in 80% or more of studied facilities. LMICs=low-income and middle-income countries.
Figure 3
Figure 3
Map of reported affordability of inhaled medicines in LMICs (A) Short-acting beta-agonist inhalers. (B) Inhaled corticosteroid inhalers. (C) Inhaled corticosteroid–long-acting beta-agonist combination inhalers. Affordability means a month's treatment costing less than a day's wage of a lowest paid government employee. LMICs=low-income and middle-income countries.
See this image and copyright information in PMC

Comment in

References

    1. Beaglehole R, Bonita R, Horton R, et al. Priority actions for the non-communicable disease crisis. Lancet. 2011;377:1438–1447. - PubMed
    1. Meghji J, Mortimer K, Agusti A, et al. Improving lung health in low-income and middle-income countries: from challenges to solutions. Lancet. 2021;397:928–940. - PubMed
    1. Asher MI, Rutter CE, Bissell K, et al. Worldwide trends in the burden of asthma symptoms in school-aged children: Global Asthma Network Phase I cross-sectional study. Lancet. 2021;398:1569–1580. - PMC - PubMed
    1. Halpin DMG, Celli BR, Criner GJ, et al. The GOLD Summit on chronic obstructive pulmonary disease in low- and middle-income countries. Int J Tuberc Lung Dis. 2019;23:1131–1141. - PubMed
    1. WHO . World Health Organization; Geneva: 2013. Global Action Plan for the prevention and control of noncommunicable diseases 2013–2020.

Publication types

MeSH terms